Альтернативные системы экспрессии рекомбинантного ИФН-?-2b человека
Диссертация
Последние достижения в геномике, протеомике и биоинженерии привели к значительному росту числа лекарственных белков, получаемых с использованием 5 биотехнологий. В технологическом процессе применяются различные методы очистки и используется целый ряд продуцентов: бактериальные и дрожжевые клетки, культуры клеток насекомых и млекопитающих, а также растения. При разработке технологии получения… Читать ещё >
Список литературы
- Болотова Н.В., Краснов В. В., Кузин Б. В., Гапонюк П. Я., Щипанова А. И. Лечение ОРВИ и гриппа у беременных женщин и детей / Эффективная фармакотерапия в акушерстве и гинекологии. № 1. — 2007. С.: 30−33.
- Волкова М.А. Интерфероны и их применение в онкогематологии // Российский биотерапевтический журнал. 2002. — № 1, Т.1. — С. 25−33.
- Ершов Ф.И. Пять десятилетий интерферона / Интерферону 50 лет. -Москва, 2007.-С. 11−34.
- Ершов Ф.И., Киселев О. И. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЕОТАР Медиа, 2005. — 368 с.
- Зулькарнаева Э.Т. Обоснование и возможности применения интерферона в комплексной терапии рака молочной железы: Автореф. дис. канд. мед. наук.-Уфа, 1999.-24 с.
- Кадагидзе З.Г. Цитокины // Практическая онкология. 2003. — Т.4, № 3. -С. 131−139.
- Киселев О.И., Ершов Ф. И., Деева Э. Г. Интерферон гамма: структура и свойства/ Интерферону — 50 лет. — Москва, 2007. — С. 35−44.
- Микеш О. Лабораторное руководство по хроматографическим и смежным методам. Часть 1. М: Мир, 1982. С. 400.
- Мкртчян Л.Н., Камалян Л. А. Интерфероны в онкологии. Ер.: Айстан, 1989.-123с.
- Ю.Патрушев Л. И. Искусственные генетические системы Т.1: Генная и белковая инженерия. М.: Наука, 2004. -526с.
- PJIC Регистр лекарственных средств. Энциклопедия лекарств. 16-й вып. /Гл. ред. Г. Л. Вышковский. — М.: «РЛС-2008», 2007. — 1456с.
- Albini A., Marchisone С., Del Grosso F. et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach // Am J Pathol. 2000, Apr. — Vol. l56(4). — P. 1381−1393.
- Yl.Amato R.J., Jac J., Hernandez-McClain J. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial // Anticancer Drugs. 2008, Jun. — Vol. 19(5). — P. 527−533.
- Archuleta TD, Armitage JO. Advances in follicular lymphoma // Semin Oncol. 2004, Apr-31 (2 Suppl 4). -P.66−71.
- Arnau J., Lauritzen C., Petersen GE., Pedersen J. Current strategies for the use of affinity tags avd tag removal for the purification of recombinant proteins // Protein Expr Purif. 2006, -Vol. 48. — P. 1−13.
- Bagheri K., Javaranl M.J., Mahboudi F., Moeini A., Zebarjadi A. Expression of human interferon gamma in Brassica napus seeds // African Journal of Biotechnology. 2010. -Vol. 9(32). — P. — 5066−5072.
- Bardor M., Faveeuw C., Fitchette AC., Gilbert D., Galas L., TrotteinF., Faye L., Lerouge P. Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha (l, 3)-fucose and core xylose // Glycobiology. 2003, Jun. -Vol. 13(6). P. 427134.
- Bock R. Plastid biotechnology: prospects for herbicide and insect resistance, metabolic engineering and molecular farming // Curr Opin Biotechnol. 2007, Apr.-Vol. 18(2).-P. 100−106.
- Bogdan Ck, Mattner J., Schleicher U. The role of type I interferons in non-viral infections // Immunol Rev.- 2004. Vol. 202. — P. 33−48.
- Borden EC, Sen GC, Uze G, Silverman RH, RansohoffRM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine // Nat Rev Drug Discov. 2007, Dec. Vol. 6(12). — P. 975−990.
- Brancho D, Tanaka N, Jaeschke A, Ventura J J, Kelkar N, Tanaha Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ Mechanism of p38 MAP kinase activation in vivo // Genes Dev. 2003, Aug. Vol. 15−17(16). -P. 1969−1978.
- Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourhis C, Lange C, Vine ND, Ma JK, Lerouge P, Faye L. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants // Glycobiology. 1999, Apr. Vol. 9(4). — P. 365−372.
- Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines // Clin Cancer Res. 2001, Jun.-Vol. 7(6).-P. 1821−1831.
- Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis // Apoptosis. 2003, Jun. Vol. 8(3). P. 237−249.
- Chen iQ, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma // Blood. 2001, Oct. Vol. 1−98(7). — P. 21 832 192.
- Desai P.N., Shrivastava N., Padh H. Production of heterologous proteins in plants: strategies for optimal expression // Biotechnol Adv. 2010 Jul-Aug. -Vol. 28(4).-P. 427−435.
- De Zoeten GA, Penswick JR, Horisberger MA, Ahl P, Schultze M, Hohn T. The expression, localization, and effect of a human interferon in plants // Virology. 1989, Sep. Vol. 172(1). -P.213−222.
- Dijkema R, Pouwels P, de Reus A, Schellekens H. Structure and expression in Escherichia coli of a cloned rat interferon-alpha gene // Nucleic Acids Res. 1984, Jan 25. Vol. 12(2). — P. 1227−1242.
- Faye, L., Boulaflous, A., Benchabane, M., Gomord, V. and Michaud, D. Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming // Vaccine. 2005. — Vol. 23. -P. 1770−1778.
- Feinstein SI, Chernajovsky Y, Chen L, Maroteaux L, Mory Y. Expression of human interferon genes using the recA promoter of Escherichia coli // Nucleic Acids Res. -1983, May 11.- Vol. 11(9). P. 2927−2941.
- Gasdaska J.R., Spenser D., Dickey L. Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna // BioProcessing J. 2003. -Vol. 3. -P. 49−56.
- Giddings G. Transgenic plants as protein factories // Curr Opin Biotechnol. -2001, Oct. Vol. 12(5). — P. 450−454.
- Gomord V, Fitchette AC, Menu-Bouaouiche L, Saint-Jore-Dupas C, Plasson C, Michaud D, Faye L. Plant-specific glycosylation patterns in the context oftherapeutic protein production // Plant Biotechnol J. 2010, Jun. — Vol. 8(5). -P. 564−587.
- Gresser I. The antitumor effects of interferon: A personal history // Biochimie. 2007. — Vol. 89. — P. 723−728.
- Grimsley N, Hohn B, Hohn T, Walden R. «Agroinfection,» an alternative route for viral infection of plants by using the Ti plasmid // Proc Natl Acad Sci USA.- 1986, May. Vol. 83(10). — P. 3282−3286.
- Guilhot F., Chastang C., Michallet M. et al. Interferon Alfa-2b combined with Cytarabine versus Interferon alone in chronic Myelogenous Leukemia // N Engl J Med. 1997. — Vol. 337. — P.223−229.
- Guilhot F, Roy L, Guilhot J, Millot F. Interferon therapy in chronic myelogenous leukemia // Hematol Oncol Clin North Am. 2004, Jun. — Vol. 18(3).-P. 585−603.
- Gutterman J. U. Cytokine therapeutics: Lessons from interferon a // Proc. Nadl. Acad. Sci. USA. 1994. — Vol. 91. — P. 1198−1205.
- I.Isaacs A., Lindenmann J. Virus interference. I. The interferon // Proc. R. Soc. Lond. Ser. 1957. — Vol. 147. — P. 258−267.
- Jana S., Deb J.K. Strategies for efficient production of heterologous proteins in Escherichia coli // Appl Microbiol Biotechnol. 2005, May. — Vol. 67(3). -P.289−298.
- Kavanagh D., Hill A.D., Djikstra B. et al. Adjuvant therapies in the treatment of stage II and III malignant melanoma // Surgeon. 2005. — Vol. 3(4). — P. 245−256.
- Kondo M., Nagano H., Hiroshi Wada H. et al. Combination of IFN-A and 5-Fluorouracil Induces Apoptosis through IFN-A/B Receptor in Human Hepatocellular Carcinoma Cells // Clin Cancer Res. 2005. -Vol. 11. — P. 1277−1286.
- Lengyel P. Tumor-suppressor genes: News about the interferon connection // Proc. Natl. Acad. Sci. USA. 1993. — Vol. 90 — P. 5893−5895.
- S9.Lessard PA, Kulaveerasingam H, York GM, Strong A, Sinskey AJ.
- Manipulating gene expression for the metabolic engineering of plants // Metab Eng. 2002, Jan. — Vol. 4(1). — P. 67−79.
- Maeyer E.D., Skup D., Prasad K.S.N, et al. Expression of a chemically synthesized human al interferon gene // Proc. Natl. Acad. Sci. USA 1982, July. — Vol. 79. — P. 4256−4259.
- Marino M.H. Expression systems for heterologous protein production // BioPharm- 1989. Vol.2. P. 18−33.
- Marschall Z., Scholz A., Cramer T. et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis // J Natl Cancer Inst. 2003, Mar. — Vol. 95(6). — P. 437−448.
- Meager A. Biological assays for interferon // J Immunol Methods. 2002. -Vol.261.-P. 21−36.
- Melamed D., Resnitzky D., Haimov I. et al. Interleukin 6 Induces DNA Binding Activity of API in Ml Myeloblasts Cells but not in a Growth Resistant Cell Derivative // Cell Growth Differ. 1993. -Vol. 4. — P. 689 698.
- Mickisch G.H., Garin A., va Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial // Lancet. 2001. — Vol. 22, N 358 (9286). — P.966−970.
- Milner AE, Grand RJ, Gregory CD. Effects of interferon-alpha on human B cells: repression of apoptosis and prevention of cell growth are independent responses of Burkitt lymphoma lines // Int J Cancer. 1995, May 4. — Vol. 61(3).-P. 348−354.
- Moen M.D., McKeage K., Plosker G.L. et al. Imatinib: a review of its use in chronic myeloid leukaemia // Drugs. 2007. — Vol. 67 (2). — P. 299−320.
- Mori M. Zhang GH. Kaido M, Okuno T, Furusawa I. Efficient production of human gamma interferon in tobacco protoplasts by genetically engineered brome mosaic virus RNAs // J Gen Virol. 1993, Jul. — Vol. 74 (Pt 7). — P. 1255−1260.
- Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer117center experience // Clin Cancer Res. 2004, Sep 15. — Vol. 10(18 Pt 2). — P. 6302S-6303S.
- Miiller C.R., Smeland S., Bauer H.C. et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series // Acta Oncol. 2005. — Vol.44(5. — P. 475−480.
- Negrier S., Escudier B., Las set C. et al. Recombinant Human Interleukin-2, recombinant human Interferon Alfa-2a, or both n metastatic renal-cell carcinoma // N Engl J Med. 1998. — Vol. 338. — P. 1272−1278.
- Neves F.O., Ho P.L., Raw I. et al. Overexpression of a synthetic gene encoding human alpha interferon in Escherichia coli // Protein Expr Purif. -2004. Vol. 35. — P. 353−359.
- OBrien S.G., Guilhot F., Larson R.A. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia // N Engl J Med. 2003. — Vol. 13, N 348(11). — P. 9 941 004.
- Ohya K, Matsumura T, Ohashi K, Onuma M, Sugimoto C. Expression of two subtypes of human IFN-alpha in transgenic potato plants // J Interferon Cytokine Res. 2001, Aug. — Vol. 21(8). — P. 595−602.118
- Parmar S. and Platanias L. C. Interferons: mechanisms of action and clinical applications // Curr Opin Oncol. 2003. — Vol. 15. — P. 431−439.
- Pestka S. The Interferons: 50 Years after their discovery, there Is much more to learn // J Biol Chem. 2007. — Vol. 282(28). — P.20 047−20 051.
- Pestka S., Krause C. D., Walter M. R. Interferons, interferon-like cytokines, and their receptors // Immunol Rev 2004. — Vol. 202. — P. 8−32.
- Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling // Pharmacol Ther. 2003 May. — Vol. 98(2). — P. 129−142.
- Pulkkanen K.J., Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status // Mol Ther. 2005. — Vol. 12(4). — P.585−98.
- Radhakrishnan R., Walter LJ., Hruza A., Reichert P., Trotta PP., Nagabhushan TL., Walter MR. Zinc mediated dimer of human interferon-a2b revealed by X-ray crystallography // Structure. 1996. — Vol. 4. — No 126. -P. 1453−1463.
- Rai M., Parh H. Expression systems for production of heterologous protein // Current Sciens. 2001. — Vol. 80. — P. 1121−1128.
- Rijckborst V, Jans sen HL. The Role of Interferon in Hepatitis B Therapy / Curr Hepat Rep. 2010 Nov-9(4):231−238. Epub 2010 Aug 26.
- Rizzetto M. Hepatitis D: clinical features and therapy // Dig Dis. 2010. -Vol. 28(1).-P. 139−143.
- Rodriguez-Villanueva J, McDonnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha // Int J Cancer. 1995, Mar. -Vol. 29−61(1). P. 110−114.
- Roos G, Leanderson T, Lundgren E. Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells // Cancer Res. -1984, Jun. Vol. 44(6). — P. 2358−2362.
- Rosano GL, Ceccarelli EA. Rare codon content affects the solubility of recombinant proteins in a codon bias-adjusted Escherichia coli strain // Microb Cell Fact. 2009, Jul. 24. — Vol. 8. — P. 41.
- Rudolph R, Lilie H. In vitro folding of inclusion body proteins // FASEB J. 1996, Jan. — Vol. 10(1). — P. 49−56.
- Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma // Oncologist. -2003. Vol. 8(5). — P. 451−458.
- Samuel C. E. Antiviral Actions of Interferons // Clin Microbiol Rev. -2001.-Vol. 14, N4.-P. 778−809.
- Sangfelt O, Erickson S, Einhorn S, Grander D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines // Oncogene. 1997, Jan 30. — Vol. 14(4). — P. 415123.
- Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest // Front Biosci. 2000, Apr 1. — Vol. 5. — P. D479-D487.
- Sangfelt O, Strander H. Apoptosis and cell growth inhibition as antitumor effector functions of interferons // Med Oncol. 2001. — Vol. 18(1). — P. 3−14.
- Santi L, Huang Z, Mason H. Virus-like particles production in green plants // Methods. 2006, Sep. — Vol. 40(1). — P. 66−76.120
- Sawahel WA. The production of transgenic potato plants expressing human alpha-interferon using lipofectin-mediated transformation // Cell Mol Biol Lett. -2002. Vol. 7(1). -P. 19−29.
- Slocombe P, Easton A, Boseley P, Burke DC. High-level expression of an interferon alpha 2 gene cloned in phage M13mp7 and subsequent purification with a monoclonal antibody // Proc Natl Acad Sci USA.- 1982, Sep. Vol. 79(18).-P. 5455−5459.
- Sen G.C., Lengyel P. The interferon system // J Biol Chem. 1992. — Vol. 267, № 8. -P. 5017−5020.
- Shepherd J., Brodin H., Cave C. et al. Pegylated interferon -2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation // Health Technol Assess. 2004. -Vol. 8, No. 39.-P. 1−125.
- Shepherd J., Jones J., Hartwell D. et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation // Health Technol Assess. 2007. — Vol. 11(11).-P. 1−205.
- Shiloach J., Fass R. Growing E. coli to hugh cell density a historical perspective on method development // Biotechnol Adv. — 2005, July. — Vol. 23, № 5. p. 345−357.
- Singh S.M., Panda A.K. Solubilization and refolding of bacterial inclusion body proteins // Biosci Bioeng. 2005, Apr. — Vol. 99(4). — P. 303−310.
- Song L, Zhao DG, Wu YJ, Li Y. Transient expression of chicken alpha interferon gene in lettuce // J Zhejiang Univ Sci B. 2008, May. — Vol. 9(5). -P. 351−355.
- Sun WH, Pabon C, Alsayed Y. et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression // Blood. 1998 Jan. — Vol. 91(2). — P. 570−576.
- Suzuki H, Brown CJ, Forney LJ, Top EM. Comparison of correspondence analysis methods for synonymous codon usage in bacteria // DNA Res. -2008, Dec. Vol. 15(6). — P. 357−365.
- Tacket C. O. Plant-based vaccines against diarrheal diseases // Trans Am Clin Climatol Assoc. 2007. — Vol. 118. — P. 79−87.
- Tacket CO. Plant-based oral vaccines: results of human trials // Curr Top Microbiol Immunol. 2009. — Vol. 332. — P. 103−117.
- Takemoto Y., Yano H., Seiya Momosaki S. Antiproliferative Effects of Interferon-aConl on Ovarian Clear Cell Adenocarcinoma In vitro and In vivo. II Clin Cancer Res. 2004. — Vol. 10. — P. 7418−7426.
- Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia // Blood. 1987, May. — Vol. 69(5). — P. 1280−1288.
- Talpaz M., Rakhit A., Rittwegwr K. et al. Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-A-2aWith and Without Cytarabine in Patientswith ChronicMyelogenous Leukemia // Clin Cancer Res.-2005.-Vol. 6247, N 11(17).-P. 6247−6255.
- Taniguchi T., Fujii-Kuriyama Y, Muramatsu M. Molecular cloning of human interferon cDNA // Proc Natl Acad Sci USA. -1980, Jul. Vol. 77(7). — P.4003−4006.
- Tedjarati S., Baker C.H., Apte S. Synergistic Therapy of Human Ovarian Carcinoma Implanted Orthotopically in Nude Mice by Optimal Biological Dose of Pegylated Interferon a Combined with Paclitaxell // Clin Cancer Res. 2002. — Vol. 8. — P. 2413−2422.
- Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, NatarajanN, Goodwin P, Arntzen CJ, Mason HS. Immunogenicity in humans of an edible vaccine for hepatitis B // Proc Natl Acad Sci USA.- 2005, Mar 1. Vol. 102(9). — P. 3378−3382.
- Thomas NS, Pizzey AR, Tiwari S, Williams CD, Yang J. pi30, pi07, and pRb are differentially regulated in proliferating cells and during cell cycle arrest by alpha-interferon // J Biol Chem. 1998, Sep 11. — Vol. 273(37). — P. 23 659−23 667.
- Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. Mechanisms of Interferon-alpha induced apoptosis in malignant cells // Oncogene. 2002, Feb 14. — Vol. 21(8). — P. 1251−1262.
- Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI, Kimchi A. Alpha Interferon Suppresses the Cyclin D3 and cdc25A Genes, Leading to a Reversible G0-Like Arrest // Mol Cell Biol. 1996. — Vol. 16 (7). -P. 3934−3944.
- Uddin S, Sweet M, Colamonici OR, Krolewski J J, Platanias LC. The vav proto-oncogene product (p95vav) interacts with the Tyk-2 protein tyrosine kinase.// FEBS Lett. 1997, Feb 10. — Vol. 403(1). — P. 31−34.
- Uprichard SL. Hepatitis C virus experimental model systems and antiviral drug research // Virol Sin. 2010, Aug. — Vol. 25(4). — P. 227−245.
- Valente C.A., Prazeres D.M.F., Cabral J.M.S. et al. Translation features of human alpha 2b interferon production in Escherichia coli II Appl Environ Microbiol. 2004, Apr. — P. 5033−5036.
- Vallejo LF, Rinas U. Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins // Microb Cell Fact. 2004, Sep 2.-Vol. 3(1).-P. 11.
- Veluthambi K., Aditya K. Gupta and Arun Sharma. The current status of plant transformation technologies // Curr. Sci. 2003. — Vol. 84 (3). — P. 368 380.
- Verch T, Yusibov V, Koprowski H. Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector // J Immunol Methods. 1998, Nov 1. — Vol. 220(1−2). — P. 69−75.
- Vincentelli R, Canaan S, Campanacci V, Valencia C, MaurinD, Frassinetti F, Scappucini-Calvo L, Bourne Y, Cambillau C, Bignon C. High-throughput automated refolding screening of inclusion bodies // Protein Sci. 2004, Oct. — Vol. 13(10). — P. 2782−2792.
- Vitale A, Pedrazzini E. Recombinant pharmaceuticals from plants: the plant endomembrane system as bioreactor // Mol Interv. 2005, Aug. — Vol. 5(4). -P. 216−225.
- Voss T, Falkner E, Ahorn H, Krystek E, Maurer-Fogy I, Bodo G, Hauptmann R. Periplasmic expression of human interferon-alpha 2c in Escherichia coli results in a correctly folded molecule I I Biochem J. -1994, Mar 15. Vol. 298. — P. 719−725.
- Wagstaff J. Renal cell cancer: is immunotherapy dead? // Ann Oncol. -2007, Jul. Vol. 18. — Suppl 9. ix 94−97.
- Wu F., Zhao D., Song L., Xu W. Heterologous expression of synthetic chicken IFN-y in transgenic tobacco plants // Biologia. 2009. — Vol. 64 (6). -P. 1115−1122.
- Zhu Z., Hughes K., HuangL., Sun B., Liu C., Li Y. Expression of human ainterferon cDNA in transgenic rice plants // Plant Cell. 1994. — Vol. 36 (2). -P. 197−204.